INVESTIGATION OF THE NEUROPROTECTIVE EFFECT OF LINAGLIPTIN AND CELIPROLOL IN RESERPINE-INDUCED OROFACIAL DYSKINESIA AND ROTENONE-INDUCED NEURODEGENERATION IN RATS
Objective: Linagliptin, an anti-diabetic agent, proven to play an important role in regulating neuronal plasticity and reduce apoptosis and neuroinflammation by activating downstream AMPK/Sirt 1 pathway, which protects mitochondrial function and suppresses intracellular ROS accumulation and shows antioxidant action. Celiprolol, a β-1selective adrenoceptor blocker used as an anti-hypertensive agent, possesses a direct scavenging activity on oxygen radicals with antioxidant properties. The current study was designed to investigate the combined neuroprotective effect of linagliptin and celiprolol.
Methods: Wistar rats of either sex were divided into different groups (n = 6). Eight groups each for Reserpine induced orofacial dyskinesia model and Rotenone induced neurodegeneration model to mimic Parkinson’s like conditions and treated or not with different doses of linagliptin and celiprolol. 24 h after the last dose, animals were subjected to behavioral, biochemical and histopathological evaluations. The data were analyzed by ANOVA and Bonferroni multiple comparison test.
Results: Reserpine treatment increased VCMs, tongue protrusion and decreased locomotor activity. Rotenone treatment decreases the motor activity and exploratory ability of the animals. Reserpine as well as rotenone treatments decrease catalase, GSH, SOD and increase the LPO levels as compared to sham group animals. Reserpine and rotenone also showed the presence of ghost cells and vacuolated cytoplasm. Linagliptin and celiprolol alone as well as in combination normalized the behavioral, biochemical and histopathological complications.
Conclusion: Linagliptin and Celiprolol showed neuroprotection by antioxidant activity as well as improved reserpine and rotenone-induced behavioral deficits. Both drugs have tenacious potential and can be used clinically with some further investigations.
2. Wojsiat J, Zoltowska KM, Laskowska Kaszub K, Wojda U. Oxidant/antioxidant imbalance in Alzheimer's disease: Therapeutic and Diagnostic Prospects. Oxidative Medicine and Cellular Longevity; 2018. p. 1–16.
3. Shim JS, Kim HG, Ju MS, Choi JG, Jeong SY, Oh MS. Effects of the hook of Uncariarhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson’s disease. J Ethnopharmacol 2009;126:361-5.
4. Hritcu L, Foyet HS, Stefan M, Mihasan M, Asongalem AE, Kamtchouing P. Neuroprotective effect of the methanolic extract of hibiscus asper leaves in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. J Ethnopharmacol 2011;137:585-91.
5. Miller RL, James Kracke M, Sun GY, Sun AY. Oxidative and inflammatory pathways in Parkinson’s disease. Neurochem Res 2009;34:55-65.
6. Danielson SR, Andersen JK. Oxidative and nitrative protein modifications in Parkinson's disease. Free Radical Biol Med 2008;44:1787-94.
7. Dong Y, Wang J, Feng DY, Qin HZ, Wen H, Yin ZM, et al. Protective effect of quercetin against oxidative stress and brain edema in an experimental rat model of subarachnoid hemorrhage. Int J Med Sci 2014;11:282-90.
8. Gengler S, Mcclen P. GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PSI mice. Neurobiology 2012;33:265-76.
9. Jayasankar K, Lixia G, Kin YT. Linagliptin, a dipeptidyl peptidase inhibitor, mitigates cognitive deficits and pathology in the 3xTg-AD mouse model of Alzheimer's disease. Mol Neurobiol 2016;321:975-83.
10. Kroller Schon S, Knorr M, Hausding M, Oelze M, Schuff A, Schell R, et al. Glucoseindependent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition. Cardiovasc Res 2012;96:140-9.
11. Wongchai K, Schlotterer A, Lin J, Humpert P, Klein T, Hammes HP, et al. Protective effects of liraglutide and linagliptin in C. elegans as a new model for glucose-induced neurodegeneration. Horm Metab Res 2015;48:70–5.
12. Chaykovska L, Alter ML, von Websky K, Hohmann M, Tsuprykov O, Reichetzeder C, et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013;31:2290–9.
13. Yao EH, Fukuda N, Matsumoto T, Katakawa M, Yamamoto C, Han Y, et al. Effects of the antioxidative ?-blocker celiprolol on endothelial progenitor cells in hypertensive rats. Am J Hypertension 2008;21:1062–8.
14. Nishioka S, Yoshioka T, Nomura A, Kato R, Miyamura M, Okada Y, et al. Celiprolol reduces oxidative stress and attenuates left ventricular remodeling induced by hypoxic stress in mice. Hypertension Res 2013;36:934–9.
15. Gurel A, Coskun O, Armutcu F, Kanter M, Ozen OA. Vitamin E against damage caused by formaldehyde in frontal cortex and hippocampus: biochemical and histological studies. J Chem Neuroanat 2005;29:173–8.
16. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 2005;64:26–31.
17. Keltner NL, Zielinski AL, Hardin MS. Drugs used for cognitive symptoms of Alzheimer‘s disease. Perspect Psychiatry Care 2001;37:31–4.
18. Vogel HG, Scholkens BA, Sandow J, Muller G, Vogel Wf. Drug discovery and evaluation: Pharmacological Assays. 2nd ed. Springer Verlag, Berlin, Germany; 2002. p. 595–643.
19. Naidu PS, Singh A, Kulkarni SK. Effect of withaniasomnifera roots extracts on haloperidolinduced orofacial dyskinesia: a possible mechanism of action. J Med Food 2003;26:107–14.
20. Shaikh S, Snobar S. Neurodegenerative disease: multifactorial conformation disease and their therapeutic interventions. J Neurodegen Dis 2003;13:1-8.
21. Carlsson A, Lindqvist M, Magnusson T. 3, 4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957;180:1200–3.
22. Neisewander JL, Castaneda E, Davis DA. Dose-dependent differences in the development of induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacol 1994;116:79–84.
23. Betarbet R, Sherer T, Mackenzie G, Garcia Osuna M, Panov A, Greenamyre Jt. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-6.
24. Verma R, Nehru B. Effect of centrophenoxine against rotenone-indued oxidative stress in an animal model of Parkinson’s disease. Neurochem Int 2009;55:369-75.
25. Burger ME, Alves A, Callegari L, Athayde FR, Nogueira CW, Zeni G, et al. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:135–40.
26. Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson’s disease in Drosophila melanogaster. J Neurosci 2004;24:10993–8.
27. Chow CK. Nutritional influence on cellular antioxidant defense systems. Am J Clin Nutr 1979;32:1066–81.
28. Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress, and aging. Free Radical Biol Med 2000;29:222–30.
29. Li Y, Powers C, Jiang N, Chopp M. Intact, injured, necrotic and apoptotic cells after focal cerebral ischemia in the rat. J Neurol Sci 1998;156:119-32.
30. Luck H. Methods of enzymatic analysis. Academic Press: New York; 1971. p. 885–93.
31. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–7.
32. Kono Y. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 1978;186:189–95.
33. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1966;99:667–76.
34. Lapointe N, St-Hilaire M, Martinoli Mg, Blanchet J, Gould P, Rouillard C, et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 2004;18:717–9.
This work is licensed under a Creative Commons Attribution 4.0 International License.